| Chronic Myeloid Leukemia |
1 |
1 |
| Antineoplastic Drug |
0 |
0.97 |
| Biologic Therapy |
0 |
0.98 |
| Tyrosine Kinase Inhibitor |
0 |
0.99 |
| Toxicology |
0 |
0.51 |
| Adverse Effects |
0 |
0.31 |
| Patient Safety |
0 |
0.3 |
| Leukemia |
0 |
0.26 |
| Cancer |
0 |
0.23 |
| Georgia |
0 |
0.16 |
| Platelet Count |
0 |
0.13 |
| Thrombus |
0 |
0.11 |
| Alabama |
0 |
0.08 |
| Blood |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| Generics |
0 |
0.08 |
| Neutrophils |
0 |
0.08 |
| New York |
0 |
0.08 |
| Remission |
0 |
0.08 |
| Tyrosine Kinase |
0 |
0.08 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Thromboembolism |
0 |
0.07 |